Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.35
  • Today's Change-0.05 / -3.57%
  • Shares traded48.54m
  • 1 Year change+121.31%
  • Beta1.1646
Data delayed at least 15 minutes, as of Mar 04 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)2.38bn
  • Net income in HKD-91.63m
  • Incorporated2006
  • Employees2.77k
  • Location
    Sihuan Pharmaceutical Holdings Group Ltd21/F, Building 2,Zhbng 2000 Bsns CtrWest BalizhuangChaoyang DistrictBEIJING 100025ChinaCHN
  • Phone+86 75 588609726
  • Fax+86 1 052278758
  • Websitehttps://www.sihuanpharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CStone Pharmaceuticals230.11m-428.53m9.24bn93.00--23.86--40.15-0.3288-0.32880.17760.26240.14871.381.681,704,542.00-27.69-39.13-54.45-60.19-12.1866.69-186.23-170.861.20-29.830.554---12.21--75.16------
Luye Pharma Group Ltd7.01bn451.08m9.67bn5.12k20.180.54526.011.380.11990.11991.864.440.20832.422.371,361,039.001.911.983.263.1666.8568.379.158.041.242.350.42270.00-1.33-0.9503-11.40-19.50-10.95--
China Traditional Chinese Med Hldg CoLtd17.71bn-300.96m9.77bn15.58k--0.415210.700.5515-0.0598-0.05983.524.670.43261.591.711,057,360.00-0.933.48-1.425.2447.6654.69-2.157.391.519.550.133321.27-8.902.89-95.79-49.14-15.28-48.82
Hbm Holdings Ltd904.99m571.49m9.91bn210.0015.384.0916.5710.950.7410.7411.152.790.38566.3232.645,801,203.0024.77-42.8730.77-53.2492.9596.1264.25-292.586.0228.630.1857---57.4347.71-87.81---55.31--
Guangzhou Innogen Pharmaceutl Grp Co Ltd-100.00bn-100.00bn11.24bn105.00--13.17----------1.85------------------------3.39--0.0769------76.18------
Fujian Haixi Pharmaceuticals Co Ltd-100.00bn-100.00bn11.41bn--------------------------------------------------47.39--15.86------
Everest Medicines Ltd967.41m-748.61m11.98bn722.00--2.49--12.38-2.32-2.322.9913.620.168413.973.041,454,751.00-13.03-29.28-14.21-31.6769.92---77.38-1,040.865.43--0.1577--461.16---23.32--16.96--
Sihuan Pharmaceutical Holdings Group Ltd2.38bn-91.63m12.80bn2.77k--2.58--5.37-0.0098-0.00980.25830.5420.18941.493.86893,796.30-3.05-3.60-5.01-5.0566.2973.13-16.08-19.741.61-1.360.1606--2.18-7.96-301.10---20.583.60
Consun Pharmaceutical Group Ltd3.71bn1.15bn14.22bn3.07k12.652.9111.633.831.341.344.335.800.56422.3512.331,173,505.0017.6014.7124.6722.8276.6275.0431.2029.563.32--0.051740.9314.5611.4216.0562.72-9.5425.83
Ascletis Pharma Inc2.69m-293.84m15.30bn208.00--6.55--5,695.75-0.3004-0.30040.00282.200.00110.266811.5911,629.77-12.10-8.46-12.73-8.8036.217.91-10,937.78-522.1214.53--0.0023---97.73-62.52-107.95---40.26--
CF PharmTech Inc686.31m31.54m15.42bn574.00489.5514.17149.6322.470.07660.07661.672.64----------------80.18--4.60--1.89--0.076--9.23---33.53------
Zai Lab Ltd3.60bn-1.37bn15.44bn1.78k--2.71--4.29-1.25-1.253.295.060.39033.124.81---14.89-30.44-21.37-36.8461.1563.11-38.15-128.852.27--0.2223--15.3356.5431.73--4.70--
Vigonvita Life Sciences Co Ltd-100.00bn-100.00bn16.58bn---------------------------------------------------94.07---1,848.73------
Data as of Mar 04 2026. Currency figures normalised to Sihuan Pharmaceutical Holdings Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.21%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 2026165.97m1.78%
BlackRock Fund Advisorsas of 06 Feb 202680.05m0.86%
GF Fund Management Co., Ltd.as of 30 Jun 202568.54m0.74%
Dimensional Fund Advisors LPas of 05 Feb 202650.85m0.55%
China Asset Management Co., Ltd.as of 30 Jun 202539.28m0.42%
Bosera Asset Management Co., Ltd.as of 30 Jun 202532.17m0.35%
BlackRock Advisors (UK) Ltd.as of 06 Feb 202616.39m0.18%
Penghua Fund Management Co., Ltd.as of 30 Jun 202511.70m0.13%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202511.12m0.12%
Norges Bank Investment Managementas of 30 Jun 202510.35m0.11%
More ▼
Data from 30 Jun 2025 - 20 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.